US2019328843A1PendingUtilityA1

Calcitonin Analogues for Treating Diseases and Disorders

41
Assignee: KEYBIOSCIENCE AGPriority: Jan 8, 2015Filed: Jul 15, 2019Published: Oct 31, 2019
Est. expiryJan 8, 2035(~8.5 yrs left)· nominal 20-yr term from priority
Inventors:Morten KarsdalKim HenriksenKim Vietz AndreassenSofie GydesenSara Toftegaard Hjuler
A61P 3/06A61P 1/16A61K 38/23
41
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Calcitonin analogues as a medicament for producing a decrease in liver triglycerides or for reducing fat accumulation in the liver of a subject are provided.

Claims

exact text as granted — not AI-modified
1 . A calcitonin analogue as a medicament for producing a decrease in liver triglycerides or for reducing fat accumulation in the liver of a subject, wherein the calcitonin analogue is in accordance with SEQ ID NO: 1 or SEQ ID NO: 2. 
     
     
         2 . The calcitonin analogue as claimed in  claim 1 , wherein the wherein the calcitonin analogue is in accordance with SEQ ID NO: 3. 
     
     
         3 . The calcitonin analogue as claimed in  claim 1 , wherein the wherein the calcitonin analogue is in accordance with SEQ ID NO: 4. 
     
     
         4 . The calcitonin analogue as claimed in  claim 1 , wherein the wherein the calcitonin analogue is in accordance with SEQ ID NO: 5. 
     
     
         5 . The calcitonin analogue as claimed in  claim 1 , wherein the wherein the calcitonin analogue is in accordance with and one of SEQ ID NOS: 6-74. 
     
     
         6 . A calcitonin analogue as a medicament for producing a decrease in liver triglycerides/reducing fat accumulation in the liver of a subject, wherein the calcitonin analogue is in accordance with any one of SEQ ID NOS: 54, 55, 57 or 58. 
     
     
         7 . A method of producing a decrease in liver triglycerides/reducing fat accumulation in the liver of a subject mammal in need thereof which comprises administering an effective amount of a calcitonin analogue as claimed in  claim 1 . 
     
     
         8 . The method as claimed in  claim 7 , wherein the amount administered is from 0.001 to 50 μg/kg/day. 
     
     
         9 . The method as claimed in  claim 7 , wherein the amount administered is from 0.01 to 5 μg/kg/day. 
     
     
         10 . The method as claimed in  claim 7  or  claim 8 , wherein the subject is a human.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.